GTX-006 (Acapodene)
Phase 2Small molecule
GTX-006 (Acapodene) is one of 2 small molecule programs targeting Prostate Intraepithelial Neoplasia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Prostate Intraepithelial Neoplasia
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GTX-006 (Acapodene). EMBL-EBI & Wellcome Sanger Institute.
- [4]